NEW YORK (GenomeWeb News) – Drug development service company Covance today announced an alliance and service agreement with M2Gen to match patients for biomarker-driven oncology trials with the right treatment or clinical trial.

Under the terms of the deal, Covance will be the preferred provider for M2Gen for DNA/RNA sequencing, gene expression analysis, and genotyping analysis services, which will be done at Covance's genomics laboratory in Seattle.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.